Sepsis Trial of Early Physical Therapy Outside the ICU

Sepsis Clinical Trial

— STEP TO IT  

Official title:

Sepsis Trial of Early Physical Therapy Outside the ICU: A Pilot Feasibility Study

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02159222
• Other study ID #: UM-HUM00073474
• Status: Terminated
• Phase: N/A
• Start date: April 2014
• Est. completion date: September 2019

Study information

• Verified date: October 2019
• Source: University of Michigan
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether an additional physical therapy program can improve the mobility and functional outcomes of patients diagnosed with severe sepsis (an illness in which the body has a severe response to bacteria or other germs and develops worsened function of a major organ such as the kidneys, heart, or lungs).

Description:

Patients who are admitted to the hospitalist service at the University of Michigan Hospital will be screened for the presence of severe sepsis. Those who are deemed eligible and provide consent will be enrolled. Study patients will receive additional physical therapy according to a protocol developed for this study in addition to the usual care recommended by their regular treating physician. Additional treatments will be individualized based on enrolled patients' baseline physical function and progress and may include standing, stretching, transferring, and walking - either with assistance or independently. Treating therapists have been trained in the use of the protocol and individualization to maintain the highest standard of patient safety. Patients will be contacted 30 days after discharge to answer questions about their health and ability to perform routine tasks at home.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 16
• Est. completion date: September 2019
• Est. primary completion date: September 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Any English-speaking patient over the age of 18 who is currently admitted to a general care floor under the care of the Medicine Faculty Hospitalist Service at the University of Michigan Health System and has severe sepsis is eligible to take part in this study.

Exclusion Criteria:

• Subjects must be deemed by the study team to give informed consent by being able to state the basic purpose of the study. Consent by a legally authorized representative (LAR) will not be sought.

Related Conditions & MeSH terms

• Sepsis
• Toxemia

Intervention

Procedure:
• Additional physical therapy

Locations

Country	Name	City	State
United States	University of Michigan	Ann Arbor	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
University of Michigan

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Readmission		At day 35 (assessed at 30 days post discharge; predicted average length of stay is 5 days).
Other	In-Hospital Mortality		Participants will be followed for the duration of their hospitalization, a predicted average length of stay of 5 days
Other	Falls		Participants will be followed for the duration of their hospitalization, a predicted average length of stay of 5 days.
Other	Arrhythmia	Clinically significant arrhythmias occurring during therapy sessions will be documented and recorded as a safety outcome.	During each study protocol physical therapy session while hospitalized
Other	Pressure ulcers	The presence and severity of pressure ulcers will be recorded.	Participants will be followed for the duration of their hospitalization, a predicted average length of stay of 5 days.
Other	Cognitive function	Enrolled patients' cognitive function will be assessed using the TICS-m instrument	At day 35 (assessed at 30 days post discharge; predicted average length of stay is 5 days).
Other	Depression	Patients will be screened for depression using the PHQ-2 instrument as part of the follow-up telephone survey.	At day 35 (assessed at 30 days post discharge; predicted average length of stay is 5 days).
Other	30-Day Post-Hospitalization Mortality		At day 35 (assessed at 30 days post discharge; predicted average length of stay is 5 days).
Primary	Change from baseline ambulation	Participants will be followed for the duration of their hospitalization, a predicted average length of stay of 5 days. This outcome will be assessed at baseline and at each study protocol physical therapy session during the index hospitalization.	At day 0 (baseline enrollment) and for the duration of the participants' hospitalization, a predicted average length of stay of 5 days.
Secondary	Change in Activities of Daily Living (ADLs) and Instrumental Activities of Daily Living (iADLs)	Baseline ADLs will be assessed using chart review. 30 day follow-up ADL and iADL function will be assessed using a telephone survey	At day 0 (baseline enrollment) and day 35 (assessed at 30 days post discharge; predicted average length of stay is 5 days)
Secondary	Discharge location	The location of discharge (home, subacute rehabilitation facility, skilled nursing facility) will be assessed at discharge for all patients enrolled in the study.	At day 5 (assessed at discharge; predicted average length of stay is 5 days)
Secondary	ICU Transfer Rate	The rate at which patients require transfer to the ICU will be assessed.	Participants will be followed for the duration of their hospitalization, an average length of stay of 5 days.
Secondary	Length of stay	The length of stay will be recorded for patients enrolled in the trial.	Participants will be followed for the duration of their hospitalization, a predicted average length of stay of 5 days.
Secondary	Employment status	For patients employed for pay prior to the index admission, employment status will be assessed by telephone survey 30 days post-discharge.	At day 35 (assessed at 30 days post discharge; predicted average length of stay is 5 days).
Secondary	Post-hospitalization physical function	Patients' physical function will be assessed 30 days after discharge using the SF-10 instrument.	At day 35 (assessed at 30 days post discharge; predicted average length of stay is 5 days).